Download PDF
Nuklearmedizin 2009; 48(05): N50-N51
DOI: 10.1055/s-0037-1621114
Case report
Schattauer GmbH

Intraoperative identification of a neuro endocrine tumour diagnosed by 68Ga-DOTATOC PET but undetectable by surgical palpation or conventional imaging

M. Freesmeyer
1   Nuclear Medicine, University Hospital Jena
,
Ch. Wurst
2   Abdominal and Vascular Surgery, University Hospital Jena
,
T. Überrueck
2   Abdominal and Vascular Surgery, University Hospital Jena
,
Th. Scholz
1   Nuclear Medicine, University Hospital Jena
,
Th. Knösel
3   Pathology, University Hospital Jena
,
S. Schulz
4   Pharmacology and Toxikology, University Hospital Jena
,
U. Settmacher
5   University Hospital Jena
› Author Affiliations
Further Information

Publication History

Received: 07 March 2009

accepted: 05 May 2009

Publication Date:
20 January 2018 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Adams S, Baum RP, Hertel A. et al. Intraoperative gamma probe detection of neuroendocrine tumors. J Nucl Med 1998; 39: 1155-1160.
    PubMedGoogle Scholar
  • 2 Buchmann I, Henze M, Engelbrecht S. et al. Comparison of 68Ga-DOTATOC PET and mIn- DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007; 34: 1617-1626.
    CrossrefPubMedGoogle Scholar
  • 3 Cirillo F, Bottini A, Lima G, Alquati P. Radioguided surgery in the treatment of gastro-entero-pancre- atic neuroendocrine tumors. Minerva Chir 2000; 55: 517-521.
    PubMedGoogle Scholar
  • 4 Fischer T, Doll C, Jacobs S. et al. Reassessment of sst2 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-1. J Clin Endocrinol Metab 2008; 93: 4519-4524.
    CrossrefPubMedGoogle Scholar
  • 5 Gabriel M, Decristoforo C, Kendler D. et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007; 48: 508-518.
    CrossrefPubMedGoogle Scholar
  • 6 Gulec SA, Baum R. Radio-guided surgery in neuroendocrine tumors. J Surg Oncol 2007; 96: 309-315.
    CrossrefPubMedGoogle Scholar
  • 7 Hodolic M, Fettich J, Repse S. et al. Factors influencing radioguided surgery of neuroendocrine tumours using 99mTc-ethylenediamine N,N'-diacetic acid/6- hydrazinopyridine-3-carboxylic acid-D-Phe1-Tyr3- octreotide. Nucl Med Commun 2008; 29: 311-317.
    CrossrefPubMedGoogle Scholar
  • 8 Hofmann M, Maecke H, Börner R. et al. Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data. Eur J Nucl Med 2001; 28: 1751-1757.
    CrossrefPubMedGoogle Scholar
  • 9 Krenning EP, Bakker WH, Kooij PP. et al. Somato- statin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med 1992; 5: 652-658.
    Google Scholar
  • 10 Meller B, Sommer K, Gerl J. et al. High energy probe for detecting lymph node metastases with 18F-FDG in patients with head and neck cancer. Nucl Med 2006; 45: 153-159.
    Google Scholar
  • 11 Pelaez N, Busquets J, Ortega M. et al. Intraoperative gamma probe detection of lymph node recurrence of insulinomas. J Surg Oncol 2005; 91: 209-211.
    CrossrefPubMedGoogle Scholar
  • 12 Van Haren RM, Fitzgerald TL. Intraoperative hand held gamma probe detection of a recurrent nonfunctional neuroendocrine tumor. J Pancreas 2008; 9: 704-707.
    Google Scholar